Genetic biomarker IDs patients with increased risk for heart damage by anthracycline chemo
Among women with breast cancer who received a type of chemotherapy called an anthracycline, those who had a certain genetic biomarker had a significantly increased risk for having anthracycline-induced congestive heart failure.
Source: ScienceDaily Headlines - Category: Science Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Cardiology | Chemotherapy | Congestive Heart Failure | Genetics | Heart | Heart Failure | Women